Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 375 of 2228 entries
View as:

Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

Phase: N/A Priority: Normal
NCT ID: NCT01194830 Org: User:
Start: 09/30/10 End: 10/31/11 Due: 10/31/12

3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study

Phase: N/A Priority: Normal
NCT ID: NCT00275444 Org: User:
Start: 03/29/02 End: - Due: -

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Phase: N/A Priority: Normal
NCT ID: NCT05155332 Org: User:
Start: 03/28/22 End: 10/31/28 Due: 10/31/29

A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

Phase: N/A Priority: Normal
NCT ID: NCT03861234 Org: User:
Start: 06/27/19 End: 11/01/23 Due: 11/01/24

Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma

Phase: N/A Priority: Normal
NCT ID: NCT00467740 Org: User:
Start: 05/31/07 End: - Due: -

Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02852824 Org: User:
Start: 08/10/16 End: 08/01/17 Due: 08/01/18

Secondary Prevention of Venous Thrombo Embolism (VTE).

Phase: N/A Priority: Normal
NCT ID: NCT00329238 Org: User:
Start: 05/31/06 End: - Due: -

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Phase: N/A Priority: Normal
NCT ID: NCT02208843 Org: User:
Start: 10/02/14 End: 06/13/17 Due: 06/13/18

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00622284 Org: User:
Start: 02/29/08 End: - Due: -

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

Phase: N/A Priority: Normal
NCT ID: NCT00601523 Org: User:
Start: 01/31/08 End: - Due: -

Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01301742 Org: User:
Start: 02/28/11 End: - Due: -

A Study in Healthy Men to Test How Different Doses of BI 1595043 Are Tolerated

Phase: N/A Priority: Normal
NCT ID: NCT04439838 Org: User:
Start: 08/13/20 End: 03/19/21 Due: 03/19/22

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

Phase: N/A Priority: Normal
NCT ID: NCT00525148 Org: User:
Start: 08/31/07 End: 08/31/15 Due: 08/31/16

Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin

Phase: N/A Priority: Normal
NCT ID: NCT02150824 Org: User:
Start: 07/31/14 End: 08/31/15 Due: 08/31/16

Bioequivalence Between WE 941 OD and Brotizolam (Lendormin®) in Healthy Adult Males

Phase: N/A Priority: Normal
NCT ID: NCT02218658 Org: User:
Start: 07/31/00 End: - Due: -

A Study to Access the Efficacy and Safety of Meloxicam in Patients With Osteoarthritis of the Knee

Phase: N/A Priority: Normal
NCT ID: NCT02183116 Org: User:
Start: 10/31/98 End: - Due: -

BIBR 953 ZW in Healthy Elderly Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02173730 Org: User:
Start: 11/30/02 End: - Due: -

The Use of Angiotensin Receptor Blockers and the Risk of Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02215733 Org: User:
Start: 02/28/11 End: - Due: -

A Prescription-Event Monitoring (PEM) Study of Tiotropium

Phase: N/A Priority: Normal
NCT ID: NCT02196194 Org: User:
Start: 09/30/02 End: - Due: -

Impact of Switching to NNRTI-based Therapy on the Quality of Life of HIV-infected Patients With Virological Suppression

Phase: N/A Priority: Normal
NCT ID: NCT02191202 Org: User:
Start: 06/30/04 End: - Due: -

Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement

Phase: N/A Priority: Normal
NCT ID: NCT00152971 Org: User:
Start: 11/30/04 End: - Due: -

Post-marketing Surveillance of Berodual® Metered-dose Inhaler in the Treatment of Chronic Obstructive Respiratory Tract Disease

Phase: N/A Priority: Normal
NCT ID: NCT02231437 Org: User:
Start: 01/31/99 End: - Due: -

Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease

Phase: N/A Priority: Normal
NCT ID: NCT02238197 Org: User:
Start: 02/28/01 End: - Due: -

Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00326768 Org: User:
Start: 05/31/06 End: 08/31/07 Due: 08/31/08

The Effect of Multiple Doses of BI 187004 on the Single-dose Pharmacokinetics of Repaglinide and Bupropion in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02305901 Org: User:
Start: 12/31/14 End: 03/31/15 Due: 03/31/16